H.C. Wainwright

H.C. Wainwright analyst Scott Buck maintained SoundHound AI Inc (NASDAQ:SOUN) with a Buy and lowered the price target from $26 to $18 on Monday. After the market closed on Thursday, SoundHound AI released its first-quarter 2025 operating results, which included revenue of $29.1...

Analysts maintained their rating/price forecast on Hut 8 Corp. (NASDAQ:HUT) following the first quarter results reported on Thursday. The company reported EPS of $(1.30), which was below the estimated $(0.24) and sales of $21.82 million fell short of the estimated $33.28 million. H.C. Wainwright...

H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ:CATX), a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer treatment. Analyst Robert Burns initiated a Buy rating and a price target of $10. The...

Cryptocurrency platform company Coinbase Global (NASDAQ:COIN) could have perfect timing with its third-quarter financial results coming as leading cryptocurrency Bitcoin (CRYPTO: BTC) trades near all-time highs. Here's what analysts and investors are watching when the company reports Wednesday...

Hut 8 Corp (NASDAQ:HUT) reported financial results Wednesday after merging with U.S. Bitcoin Corporation (USBTC) in November 2023. The results came amid an exciting earnings season. Here are some key analyst takeaways. Needham analyst John Todaro maintained a Buy rating, while raising the price...

Canoo Inc (NASDAQ: GOEV) shares were tanking in early trading on Tuesday after the company issued weak 2024 revenue guidance. In early March, the company had announced a 1-for-23 reverse stock split. The company was following a “prudent” approach to scale its manufacturing while...

Shares of Rain Oncology Inc (NASDAQ: RAIN) recovered in early trading on Tuesday, after having plummeted on disappointing cancer study data. Here are some key analyst takeaways from the company’s decision to halt studies for its lead candidate as a treatment for dedifferentiated (DD)...

Analysts are sizing up the second quarter financial results from Plug Power Inc (NASDAQ: PLUG) and the opportunity the company could have from the Inflation Reduction Act and a production tax credit. The Plug Power Analysts: BMO analyst Ameet Thakkar has a Market Perform rating and raises the...

Plug Power Inc (NASDAQ: PLUG) reported a larger-than-expected first-quarter GAAP loss even as revenues nearly doubled to $140.8 million. KeyBanc Capital Markets On Plug Power: Analyst Leo Mariani maintained an Overweight rating and a price target of $40 for the company. Analyst Mariani said in the...

Plug Power, Inc. (NASDAQ: PLUG) shares are higher after the hydrogen fuel cell energy company reported fourth-quarter results. The Plug Power Analysts: RBC Capital Markets analyst Joseph Spak maintained an Outperform rating on Plug Power shares and reduced the price target from $39 to $33....

Plug Power Inc. (NASDAQ: PLUG) reported mixed quarterly results Tuesday. Here's what the Street had to say.  The Plug Power Analysts: Morgan Stanley analyst Stephen Byrd maintained an Overweight rating and $43 price target on Plug Power shares. H.C. Wainwright analyst Amit Dayal...

Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX). The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target. The Unity Biotech...

The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: ABUS). The Arbutus Analyst: Ed Arce raffirmed a Buy rating on shares of Arbutus Biopharma Corp. with a $10 price target.  The Arbutus Takeaways: On Tuesday, Arbutus...

H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a  Buy rating on shares of ChemoCentryx, Inc. with a $28 price target.  The ChemoCentryx Takeaways:...

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%.  The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from...